The choice among these three is made by matching the biologic to the tissue you are trying to influence, not by ranking them against each other. PRP, bone marrow aspirate concentrate, and micro-fragmented adipose start from different tissue, are processed differently, and carry different mechanisms of action.1 The clinical question that decides it is which tissue is generating your symptom, and that is answered by examination and imaging rather than by preference.
Key takeaways
- The three are not interchangeable products at different price points. They are different starting substrates with different mechanisms.1
- The selection follows the tissue target: joint space, tendon or ligament interface, subchondral or marrow region, or disc.
- In a randomized knee osteoarthritis trial, 175 of 195 allocated patients completed 12 months across three arms — BMAC 111, PRP 34, hyaluronic acid 30 — with Kellgren-Lawrence grades II to IV.2
- In that trial BMAC showed greater clinical improvement than PRP and hyaluronic acid through 12 months, and all three were safe with minimal adverse events.2
- For advanced knee osteoarthritis, PRP is discussed as a bridge therapy prior to arthroplasty. No orthobiologic regrows or regenerates cartilage.
The decision starts with the target tissue
Before any of the three is named, the evaluation has to establish what is actually driving the symptom. A tendon interface problem, an inflamed joint space, a subchondral bone region, and a disc are four different targets, and a biologic that suits one is not thereby suited to the others.
This is why we treat orthobiologics as a category containing genuinely different tools rather than as one therapy with three brand names.
What separates the three preparations
PRP concentrates platelets from your own blood and works largely through platelet-derived signaling. BMAC is drawn from bone marrow and carries a different cellular and signaling profile. Lipogems is adipose tissue that has been micro-fragmented rather than enzymatically processed. A review of the mechanisms behind the first two describes them as distinct rather than graded versions of one another.1
Delivery is part of the choice, not an afterthought
Intraosseous and subchondral delivery of PRP targets the bone beneath the joint surface rather than the joint space. When imaging and symptoms point to that region, the delivery route matters as much as the preparation, and image guidance is what makes the distinction real rather than nominal.
What the comparative trial evidence actually shows
A randomized trial in knee osteoarthritis compared bone marrow aspirate concentrate against platelet-rich plasma and hyaluronic acid. Of 195 patients allocated, 175 completed the 12-month study: 111 in the BMAC arm, 34 in the PRP arm, and 30 in the hyaluronic acid arm, with Kellgren-Lawrence grades II to IV distributed without significant differences between groups.2
BMAC showed greater clinical improvement than PRP and hyaluronic acid across most outcome measures through 12 months, PRP held a modest and non-significant advantage over hyaluronic acid, and all three were safe with minimal adverse events.2
What that trial does not settle
The arms were markedly unequal in size, follow-up stopped at 12 months, and Lipogems was not studied. A trial result in knee osteoarthritis does not transfer to a tendon problem or a disc, and a group-level difference does not tell you what your individual response will be.
How the choice is made in the evaluation
The Clinical Evaluation is paid and physician-led, and it is where the decision is actually made rather than confirmed. Bring your MRI or X-ray reports; the more precisely the tissue target can be described, the less guesswork enters the selection.
What gets determined
- Which tissue is generating the primary symptom, and whether the subchondral region is involved
- Whether joint-space, tendon, intraosseous, or intradiscal delivery matches that target
- Whether PRP, BMAC, or micro-fragmented adipose is the better fit for the identified indication
- What a prior course that did not deliver tells us about the original target assumption
- Whether systemic and metabolic factors are working against the repair environment
The structure of that visit is described in our approach to conservative-first planning, and the wider evidence base is collected in the Regen.MD library.
The advanced knee is a distinct conversation
When imaging shows end-stage change, PRP is discussed as a bridge therapy prior to arthroplasty rather than as a repair. That framing is not a hedge, it is what the trial evidence supports, and the detail is on our bone on bone knee PRP page.
When conservative care has been exhausted
Regen.MD is conservative-first, and Dr. Gurpreet Singh Padda, MD, MBA, MHP is a surgeon. When conservative measures have genuinely been exhausted, surgery is available and is discussed openly. It follows exhausted conservative care rather than opening the conversation.
Find out what is actually driving your pain
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call (314) 295-3000 or text (314) 886-5902.
How the procedure is governed here
Bone marrow aspirate concentrate is a near-universal protocol, and Regen.MD follows the American Society of Interventional Pain Physicians (ASIPP) guidelines for regenerative procedures. Candidacy, technique and aftercare are set in the physician-led evaluation rather than by a standing rule applied to everyone.
Frequently asked questions
Is one of these three simply better than the others?
The comparative evidence does not support a universal ranking. In one randomized trial of knee osteoarthritis, BMAC produced greater clinical improvement than PRP or hyaluronic acid across most measures through 12 months, but the arms were unequal in size and Lipogems was not in that trial at all.2
What the trial supports is a comparison within one condition over one year, not a general hierarchy. The conditions we apply this reasoning to are listed on our conditions page.
My first PRP did not work. Does that mean I should move to BMAC?
Not automatically. A course that did not deliver is a reason to re-examine whether the target tissue was correctly identified, whether delivery reached it, and whether something systemic was working against the repair. Escalating the biologic without answering those questions repeats the original assumption.
The failure patterns we look for are set out on our page on why PRP injections fail.
Is Lipogems the same thing as BMAC?
No. Lipogems is micro-fragmented adipose tissue; BMAC is bone marrow aspirate concentrate. They start from different tissue, are processed differently, and are selected for different clinical situations.1
They are frequently compared because both are discussed after PRP, which is not a clinical reason to treat them as equivalent. Each is described under orthobiologic services.
Does the same reasoning apply to spine problems?
The reasoning does; the tools change. When the target is the disc rather than a joint surface or a tendon, delivery and goals are different enough that the knee comparison does not transfer directly. The first question is still which tissue is generating the symptom.
The spine pathway is covered on our back pain without surgery page.
Sources
- Lana JFSD, et al. “Platelet-rich plasma vs bone marrow aspirate concentrate: An overview of mechanisms of action and orthobiologic synergistic effects.” World Journal of Stem Cells, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC7933989/
- Dulic O, Rasovic P, Lalic I, Kecojevic V, et al. “Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.” Medicina (Kaunas), 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8623697/